Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.

British journal of haematology - 1 Jan 2010

Isotani Mayu, Yamada Osamu, Lachowicz Joshua L, Tamura Kyoichi, Yagihara Hiroko, Fujino Yasuhito, Ono Kenichiro, Washizu Tsukimi, Bonkobara Makoto

Abstract excerpt

The purpose of the current study was to investigate the mutation status of KIT in feline mast cell tumours (MCTs) and to examine the effects of tyrosine kinase inhibition on the phosphorylation of mutant kit in vitro and in clinical cases of cats. Sequence analysis of KIT identified mutations in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Cat Diseases
Share to Cats

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Imatinib Mesylate

Share to Immunoglobulin D

Share to Mastocytosis

Share to Piperazines

Source

Identifiers

PMID: 19804453
DOI: 10.1111/j.1365-2141.2009.07926.x

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-19804453-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.PMID 19804453Read ↗

Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatmentSemantic proximity Read ↗

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.Semantic proximity Read ↗

Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.Semantic proximity Read ↗

Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors.Semantic proximity Read ↗

Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy.Semantic proximity Read ↗

Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.Semantic proximity Read ↗

Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.Semantic proximity Read ↗

Clustering of Activating Mutations in c-KIT’s Juxtamembrane Coding Region in Canine Mast Cell NeoplasmsSemantic proximity Read ↗

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinibSemantic proximity Read ↗

Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumorsSemantic proximity Read ↗

Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours.Semantic proximity Read ↗

A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.